FindTrial
Sign In

Phase 3 study of cetirizine dry syrup in children suffering from atopic dermatitis.

Phase 3 study of cetirizine dry syrup in children suffering from atopic dermatitis.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220120
Enrollment
278
Registered
2005-09-13
Start date
2005-09-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

investigational material(s) Generic name etc : Cetirizine INN of investigational material : Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigational mat

Sponsors

GlaxoSmithKline K.K.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age: 3 to 14, Children with atopic dermatitis, patients eligible for evaluation of pruitus, etc.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Change in the severity of pruritus, safety etc.—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026